SHetA2: Promising Oral Therapy for HPV-Associated Cervical Disease

Why in News?

The Indian Council of Medical Research–National Institute of Cancer Prevention and Research (ICMR-NICPR) has validated SHetA2 for further development in India. Announced on 29 July 2026, this oral small-molecule therapy targets Human Papillomavirus (HPV)-associated cervical disease and has been transferred to Emcure Pharmaceuticals for larger human clinical trials. The development marks an important step towards innovative treatments for cervical precancer and cancer in India.

About SHetA2

SHetA2 is a new oral drug being studied to treat cervical lesions caused by HPV. Unlike HPV vaccines that prevent infection, SHetA2 aims to treat existing HPV-related precancerous and cancerous lesions.

A persistent infection with high-risk Human Papillomavirus (HPV) is the main cause of cervical cancer. The virus produces two main proteins, E6 and E7, that interfere with the body’s natural ability to stop tumors. The E6 protein breaks down the p53 protein, which helps repair DNA and triggers cell death when needed. At the same time, the E7 protein disables the Rb protein, leading to uncontrolled cell growth and tumor formation.

SHetA2 works by blocking the actions of these viral proteins, allowing the p53 and Rb proteins to function normally again. This targeted approach helps remove HPV-related abnormal cells while causing less harm to healthy cells.

The therapy is being developed for the treatment of:

• Cervical Intraepithelial Neoplasia (CIN) – a precancerous condition of the cervix.
• Cancerous cervical lesions associated with persistent HPV infection.

It is important to note that SHetA2 does not prevent HPV infection and should not be considered a substitute for HPV vaccination.

Preclinical studies have demonstrated favourable oral bioavailability, safety, tolerability, and selective activity against HPV-transformed cells, making the molecule a promising candidate for future cancer therapy.

Related Information

SHetA2 was created through a joint research project involving the ICMR–National Institute of Cancer Prevention and Research (NICPR) and the Stephenson Cancer Center, University of Oklahoma (USA).

After being validated by ICMR-NICPR, the technology was handed over to Emcure Pharmaceuticals for further development in India.

In the United States, the U.S. Food and Drug Administration (USFDA) has approved an application for an Investigational New Drug (IND No. 156700) for SHetA2. The drug is now in Phase I clinical trials (NCT04928508) for patients with advanced or recurrent ovarian, cervical, and endometrial cancers.

The World Health Organization (WHO) states that cervical cancer is a major cause of cancer deaths among women worldwide. India has a significant number of cervical cancer cases. Preventing this cancer through HPV vaccination, regular screening, and prompt treatment of early lesions is key to controlling cervical cancer.

SHetA2 Exam-Oriented Facts

• Drug Name: SHetA2.
• Type: Oral small-molecule investigational therapy.
• Target Disease: HPV-associated cervical precancer and cervical cancer.
• Target Proteins: HPV E6 and E7 oncoproteins.
• Mechanism: Restores the tumour suppressor functions of p53 and Rb proteins.
• Not a Vaccine: Treats HPV-induced disease but does not prevent HPV infection.
• Target Lesions: Cervical Intraepithelial Neoplasia (CIN 1, CIN 2, CIN 3) and cervical cancer.
• Indian Validation: ICMR–National Institute of Cancer Prevention and Research (NICPR).
• Industry Partner (India): Emcure Pharmaceuticals.
• International Collaboration: Stephenson Cancer Center, University of Oklahoma (USA).
• USFDA Status: Investigational New Drug (IND No. 156700) approved for clinical investigation.
• Clinical Trial: Phase I (NCT04928508) for ovarian, cervical, and endometrial cancers.
• HPV: A DNA virus; persistent infection with high-risk types (especially HPV-16 and HPV-18) is the primary cause of cervical cancer.
• p53 Function: Regulates DNA repair, cell cycle arrest, and apoptosis.
• Rb Function: Controls the transition from the G1 phase to the S phase of the cell cycle.